{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:43:44Z","timestamp":1792676624952,"version":"4.5.0"},"reference-count":120,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Health and Medical Research Fund (HMRF)","award":["15161881"],"award-info":[{"award-number":["15161881"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Ovarian cancer is the deadliest gynecological cancer, leading to over 152,000 deaths each year. A late diagnosis is the primary factor causing a poor prognosis of ovarian cancer and often occurs due to a lack of specific symptoms and effective biomarkers for an early detection. Currently, cancer antigen 125 (CA125) is the most widely used biomarker for ovarian cancer detection, but this approach is limited by a low specificity. In recent years, multimarker panels have been developed by combining molecular biomarkers such as human epididymis secretory protein 4 (HE4), ultrasound results, or menopausal status to improve the diagnostic efficacy. The risk of ovarian malignancy algorithm (ROMA), the risk of malignancy index (RMI), and OVA1 assays have also been clinically used with improved sensitivity and specificity. Ongoing investigations into novel biomarkers such as autoantibodies, ctDNAs, miRNAs, and DNA methylation signatures continue to aim to provide earlier detection methods for ovarian cancer. This paper reviews recent advancements in molecular biomarkers for the early detection of ovarian cancer.<\/jats:p>","DOI":"10.3390\/ijms231912041","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T21:07:11Z","timestamp":1665436031000},"page":"12041","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":255,"title":["Molecular Biomarkers for the Early Detection of Ovarian Cancer"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-8911","authenticated-orcid":false,"given":"Ruiqian","family":"Zhang","sequence":"first","affiliation":[{"name":"Departments of Obstetrics and Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle K. Y.","family":"Siu","sequence":"additional","affiliation":[{"name":"Departments of Obstetrics and Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hextan Y. S.","family":"Ngan","sequence":"additional","affiliation":[{"name":"Departments of Obstetrics and Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4034-7469","authenticated-orcid":false,"given":"Karen K. L.","family":"Chan","sequence":"additional","affiliation":[{"name":"Departments of Obstetrics and Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA. Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2022.04.021","article-title":"State of the science: Contemporary front-line treatment of advanced ovarian cancer","volume":"166","author":"Hinchcliff","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Bartoletti, M., Musacchio, L., Giannone, G., Tuninetti, V., Bergamini, A., Scambia, G., Lorusso, D., Valabrega, G., Mangili, G., and Puglisi, F. (2021). Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors. Cancer Treat. Rev., 101.","DOI":"10.1016\/j.ctrv.2021.102298"},{"key":"ref_5","first-page":"792","article-title":"Current first-line therapy for ovarian cancer: A comprehensive review","volume":"33","author":"Pierce","year":"2017","journal-title":"Obstet. Gynecol. Surv."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Qiao, L., Chen, X., Xi, X., Chen, X., Zhang, P., Dong, H., Wu, X., and Chen, X. (2020). Correlation analysis and clinical significance of CA125, HE4, DDI, and FDP in type II epithelial ovarian cancer. Medicine, 99.","DOI":"10.1097\/MD.0000000000023329"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ejso.2013.11.028","article-title":"Conservative treatment of early stage ovarian cancer: Oncological and fertility outcomes","volume":"40","author":"Zapardiel","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ygyno.2008.07.006","article-title":"Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?","volume":"111","author":"Havrilesky","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Braat, D.D.M. (1997). Diagnosis and management of ovarian disorders. Eur. J. Obstet. Gynecol. Reprod. Biol., 72.","DOI":"10.1016\/S0301-2115(96)02679-6"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/13697137.2018.1433656","article-title":"The role of transvaginal ultrasound in screening for ovarian cancer","volume":"21","author":"Campbell","year":"2018","journal-title":"Climacteric"},{"key":"ref_12","first-page":"350","article-title":"Ovarian cancer screening in the general population","volume":"41","author":"Mathis","year":"2020","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1476-4598-13-129","article-title":"MUC16 (CA125): Tumor biomarker to cancer therapy, a work in progress","volume":"13","author":"Felder","year":"2014","journal-title":"Mol. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ygyno.2006.09.028","article-title":"CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish \u201cMALOVA\u201d Ovarian Cancer Study","volume":"104","author":"Christensen","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1258\/acb.2011.011117","article-title":"The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: The pivotal role of the clinical laboratory","volume":"48","author":"Sturgeon","year":"2011","journal-title":"Ann. Clin. Biochem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/s41416-021-01697-z","article-title":"Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer","volume":"126","author":"Mukama","year":"2022","journal-title":"Br. J. Cancer."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"E465","DOI":"10.3399\/BJGP.2020.0859","article-title":"CA125 test result, test-to-diagnosis interval, and stage in ovarian cancer at diagnosis: A retrospective cohort study using electronic health records","volume":"71","author":"Funston","year":"2021","journal-title":"Br. J. Gen. Pract."},{"key":"ref_18","first-page":"192","article-title":"Is postoperative CA125 level in patients with epithelial ovarian cancer reliable to guess the optimality of surgery?","volume":"32","author":"Ghaemmaghami","year":"2011","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Gu, Z., He, Y., Zhang, Y., Chen, M., Song, K., Huang, Y., Li, Q., and Di, W. (2018). Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer. J. Transl. Med., 16.","DOI":"10.1186\/s12967-018-1489-4"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2012.09.034","article-title":"The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass","volume":"128","author":"Chan","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/AOG.0b013e31819cda77","article-title":"Results from four rounds of ovarian cancer screening in a randomized trial","volume":"113","author":"Partridge","year":"2009","journal-title":"Obstet. Gynecol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Qing, X., Liu, L., and Mao, X. (2022). A clinical diagnostic value analysis of serum CA125, CA199, and HE4 in women with early ovarian cancer : Systematic review and meta-analysis. Comput. Math. Methods Med., 2022.","DOI":"10.1155\/2022\/9339325"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1155\/2013\/917898","article-title":"OC125, M11 and OV197 epitopes are not uniformly distributed in the tandem-repeat region of CA125 and require the entire SEA domain","volume":"34","author":"Bressan","year":"2013","journal-title":"Dis. Markers."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9942","DOI":"10.3390\/ijms13089942","article-title":"Methods for identification of CA125 from ovarian cancer ascites by high resolution mass spectrometry","volume":"13","author":"Weiland","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wang, Y.-S., Ren, S.-F., Jiang, W., Lu, J.-Q., Zhang, X.-Y., Li, X.-P., Cao, R., and Xu, C.-J. (2021). CA125-Tn ELISA assay improves specificity of pre-operative diagnosis of ovarian cancer among patients with elevated serum CA125 levels. Ann. Transl. Med., 9.","DOI":"10.21037\/atm-20-8053"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1039\/D0AN01701A","article-title":"Affinity-free enrichment and mass spectrometry analysis of the ovarian cancer biomarker CA125 (MUC16) from patient-derived ascites","volume":"146","author":"Etzel","year":"2021","journal-title":"Analyst"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1021\/acsabm.1c00324","article-title":"Molybdenum disulfide supported on metal-organic frameworks as an ultrasensitive layer for the electrochemical detection of the ovarian cancer biomarker CA125","volume":"4","author":"Li","year":"2021","journal-title":"ACS Appl. Bio Mater."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.7150\/jca.48531","article-title":"Exosomal CA125 as A promising biomarker for ovarian cancer diagnosis","volume":"11","author":"Chen","year":"2020","journal-title":"J. Cancer."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/1099800404274445","article-title":"Introducing the MUC16 gene: Implications for prevention and early detection in epithelial ovarian cancer","volume":"6","author":"McLemore","year":"2005","journal-title":"Biol. Res. Nurs."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/CBM-2008-4104","article-title":"Glycoforms of CA125 antigen as a possible cancer marker","volume":"4","author":"Jankovic","year":"2008","journal-title":"Cancer Biomark."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1155\/2008\/601583","article-title":"Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis","volume":"25","author":"Saldova","year":"2008","journal-title":"Dis. Markers."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/jalm\/jfz012","article-title":"Exploratory analysis of CA125-MGL and -STn glycoforms in the differential diagnostics of pelvic masses","volume":"5","author":"Salminen","year":"2020","journal-title":"J. Appl. Lab. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s42003-020-01191-x","article-title":"Glycovariant-based lateral flow immunoassay to detect ovarian cancer\u2013associated serum CA125","volume":"3","author":"Bayoumy","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/ijc.34111","article-title":"Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer","volume":"151","author":"Jain","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1373\/jalm.2018.028266","article-title":"Europium nanoparticle-based sialyl-Tn monoclonal antibody discriminates epithelial ovarian cancer-associated CA125 from benign sources","volume":"4","author":"Gidwani","year":"2019","journal-title":"J. Appl. Lab. Med."},{"key":"ref_36","first-page":"269","article-title":"Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers","volume":"33","author":"Yoshikawa","year":"2012","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3390\/cancers12071931","article-title":"Multi-marker longitudinal algorithms incorporating HE4 and CA125 in ovarian cancer screening of postmenopausal women","volume":"12","author":"Blyuss","year":"2020","journal-title":"Cancers"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1097\/IGC.0b013e318256488a","article-title":"Ovarian cancer screening: Development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials","volume":"22","author":"Skates","year":"2012","journal-title":"Int. J. Gynecol. Cancer."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1002\/cncr.28183","article-title":"A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value","volume":"119","author":"Lu","year":"2013","journal-title":"Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"James, N.E., Chichester, C., and Ribeiro, J.R. (2018). Beyond the biomarker: Understanding the diverse roles of human epididymis protein 4 in the pathogenesis of epithelial ovarian cancer. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00124"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"22655","DOI":"10.3390\/ijms141122655","article-title":"HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival","volume":"14","author":"Jiang","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Bingle, L., Cross, S.S., High, A.S., Wallace, W.A., Rassl, D., Yuan, G., Hellstrom, I., Campos, M.A., and Bingle, C.D. (2006). WFDC2 (HE4): A potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir. Res., 7.","DOI":"10.1186\/1465-9921-7-61"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.4049\/jimmunol.2000281","article-title":"HE4 overexpression by ovarian cancer promotes a suppressive tumor immune microenvironment and enhanced tumor and macrophage PD-L1 expression","volume":"206","author":"Singh","year":"2021","journal-title":"J. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1586\/erm.09.39","article-title":"HE4 as a biomarker for ovarian and endometrial cancer management","volume":"9","author":"Li","year":"2009","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e22624","DOI":"10.1002\/jcla.22624","article-title":"Diagnostic performance of CA 125, HE4, and risk of ovarian malignancy algorithm for ovarian cancer","volume":"33","author":"Kim","year":"2019","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejogrb.2018.10.008","article-title":"Diagnostic value of HE4 in ovarian cancer: A meta-analysis","volume":"231","author":"Huang","year":"2018","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/14737140.2017.1360138","article-title":"The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: A systematic review","volume":"17","author":"Scaletta","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Hamed, E.O., Ahmed, H., Sedeek, O.B., Mohammed, A.M., Abd-Alla, A.A., and Ghaffar, H.M.A. (2013). Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Diagn. Pathol., 8.","DOI":"10.1186\/1746-1596-8-11"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Barr, C.E., Funston, G., Jeevan, D., Sundar, S., Mounce, L.T.A., and Crosbie, E.J. (2022). The performance of HE4 alone and in combination with CA125 for the detection of ovarian cancer in an enriched primary care population. Cancers, 14.","DOI":"10.3390\/cancers14092124"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1515\/cclm-2021-0510","article-title":"Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics","volume":"59","author":"Lycke","year":"2021","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1471-0528.1990.tb02448.x","article-title":"A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer","volume":"97","author":"Jacobs","year":"1990","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/AOG.0b013e318195ad17","article-title":"The accuracy of risk scores in predicting ovarian malignancy: A systematic review","volume":"113","author":"Geomini","year":"2009","journal-title":"Obstet. Gynecol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1471-0528.1996.tb09882.x","article-title":"Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses","volume":"103","author":"Tingulstad","year":"1996","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/00006250-199903000-00028","article-title":"The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals","volume":"93","author":"Tingulstad","year":"1999","journal-title":"Obstet. Gynecol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejogrb.2009.02.048","article-title":"Comparison of four malignancy risk indices in the preoperative evaluation of patients with pelvic masses","volume":"144","author":"Yamamoto","year":"2009","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_57","unstructured":"(2011). Ovarian Cancer: The Recognition and Initial Management of Ovarian Cancer, National Collaborating Centre for Cancer (UK)."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13048-020-00643-6","article-title":"Comparison of the predictive performance of risk of malignancy indexes 1\u20134, HE4 and risk of malignancy algorithm in the triage of adnexal masses","volume":"13","author":"Hada","year":"2020","journal-title":"J. Ovarian Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ygyno.2012.11.022","article-title":"Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay","volume":"128","author":"Bristow","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3390\/diagnostics11081440","article-title":"Salvaging detection of early-stage ovarian malignancies when ca125 is not informative","volume":"11","author":"Dunton","year":"2021","journal-title":"Diagnostics"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/AOG.0b013e31821b5118","article-title":"Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors","volume":"117","author":"Ueland","year":"2011","journal-title":"Obstet. Gynecol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"78.e1","DOI":"10.1016\/j.ajog.2013.09.017","article-title":"Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer","volume":"210","author":"Longoria","year":"2014","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_64","first-page":"14141","article-title":"Early diagonosis of ovarian cancer: Serum HE4, CA125 and ROMA model","volume":"13","author":"Wang","year":"2021","journal-title":"Am. J. Transl. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2147\/CMAR.S199400","article-title":"Clinical value of ROMA index in diagnosis of ovarian cancer: Meta-analysis","volume":"11","author":"Cui","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"17308","DOI":"10.1038\/s41598-021-96552-9","article-title":"Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: A meta-analysis","volume":"11","author":"Suri","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Oranratanaphan, S., Wanishpongpan, S., Termrungruanglert, W., and Triratanachat, S. (2018). Assessment of diagnostic values among CA-125, RMI, HE4, and ROMA for cancer prediction in women with nonfunctional ovarian cysts. Obstet. Gynecol. Int., 2018.","DOI":"10.1155\/2018\/7821574"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2011.02.022","article-title":"No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting","volume":"121","author":"Jacob","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cca.2014.09.028","article-title":"Clinical performance of two multi-marker blood tests for predicting malignancy in women with an adnexal mass","volume":"438","author":"Grenache","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Ngu, S.F., Chai, Y.K., Choi, K.M., Leung, T.W., Li, J., Kwok, G.S.T., Chu, M.M.Y., Tse, K.Y., Cheung, V.Y.T., and Ngan, H.Y.S. (2022). Diagnostic performance of Risk of Malignancy Algorithm (ROMA), Risk of Malignancy Index (RMI) and expert ultrasound assessment in a pelvic mass classified as inconclusive by International Ovarian Tumour Analysis (IOTA) Simple Rules. Cancers, 14.","DOI":"10.3390\/cancers14030810"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/ijgc-2021-002565","article-title":"ESGO\/ISUOG\/IOTA\/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors","volume":"31","author":"Timmerman","year":"2021","journal-title":"Int. J. Gynecol. Cancer."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"van Calster, B., Valentin, L., Froyman, W., Landolfo, C., Ceusters, J., Testa, A.C., Wynants, L., Sladkevicius, P., van Holsbeke, C., and Domali, E. (2020). Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: Multicentre cohort study. BMJ, 370.","DOI":"10.1136\/bmj.m2614"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tem.2021.12.003","article-title":"Emerging roles for folate receptor FOLR1 in signaling and cancer","volume":"33","author":"Nawaz","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ab.2004.12.026","article-title":"Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay","volume":"338","author":"Parker","year":"2005","journal-title":"Anal. Biochem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/bjc.2014.567","article-title":"Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: Implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study","volume":"111","author":"Madore","year":"2014","journal-title":"Br. J. Cancer."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.clinbiochem.2013.03.010","article-title":"Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients","volume":"46","author":"Leung","year":"2013","journal-title":"Clin. Biochem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/ijc.29937","article-title":"Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression","volume":"138","author":"Kurosaki","year":"2016","journal-title":"Int. J. Cancer."},{"key":"ref_78","first-page":"1918","article-title":"Diagnostic value of carbohydrate antigen 72-4 combined with carbohydrate antigen 15.3 in ovarian cancer, cervical cancer and endometrial cancer","volume":"25","author":"Li","year":"2020","journal-title":"J. BU ON"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1155\/2013\/984641","article-title":"Is CA72-4 a useful biomarker in differential diagnosis between ovarian endometrioma and epithelial ovarian cancer?","volume":"35","author":"Anastasi","year":"2013","journal-title":"Dis. Markers."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3343\/alm.2020.40.1.40","article-title":"Clinical usefulness of cancer antigen (CA) 125, human epididymis 4, and CA72-4 levels and risk of ovarian malignancy algorithm values for diagnosing ovarian tumors in Korean patients with and without endometriosis","volume":"40","author":"Shin","year":"2020","journal-title":"Ann. Lab. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s13277-012-0381-8","article-title":"Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer","volume":"33","author":"Granato","year":"2012","journal-title":"Tumour Biol. J. Int. Soc. Oncodev. Biol. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s43032-020-00368-3","article-title":"NFAT overexpression correlates with CA72-4 and poor prognosis of ovarian clear-cell carcinoma subtype","volume":"28","author":"Xin","year":"2021","journal-title":"Reprod. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1006\/gyno.1993.1026","article-title":"Serum and tissue measurements of CA72-4 in ovarian cancer patients","volume":"48","author":"Negishi","year":"1993","journal-title":"Gynecol. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/1078-0432.CCR-16-0316","article-title":"S Mesrine, ovarian cancer in the European EPIC cohort","volume":"22","author":"Terry","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jogoh.2018.03.010","article-title":"Evaluation of HE4 and TTR for diagnosis of ovarian cancer : Comparison with CA-125","volume":"47","author":"Zheng","year":"2018","journal-title":"J. Gynecol. Obstet. Hum. Reprod."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1002\/pmic.200500093","article-title":"Characterization of serum biomarkers for detection of early stage ovarian cancer","volume":"125","author":"Kozak","year":"2005","journal-title":"Proteomics"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Scholz, C., Heublein, S., Lenhard, M., Friese, K., Mayr, D., and Jeschke, U. (2012). Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients. BMC Res. Notes, 5.","DOI":"10.1186\/1756-0500-5-551"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.clinbiochem.2004.04.009","article-title":"Human kallikrein 11: An indicator of favorable prognosis in ovarian cancer patients","volume":"37","author":"Diamandis","year":"2004","journal-title":"Clin. Biochem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ygyno.2015.06.021","article-title":"A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer\u2014An international multicenter study in women with an ovarian mass","volume":"138","author":"Karlsen","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ijgo.12371","article-title":"Comparison of the Copenhagen Index versus ROMA for the preoperative assessment of women with ovarian tumors","volume":"140","author":"Minar","year":"2018","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ygyno.2021.05.001","article-title":"Copenhagen Index versus ROMA in preoperative ovarian malignancy risk stratification: Result from the first Vietnamese prospective cohort study","volume":"162","author":"Tran","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Carreras-Dieguez, N., Glickman, A., Munmany, M., Casanovas, G., Agust\u00ed, N., D\u00edaz-Feijoo, B., Saco, A., S\u00e1nchez, B., Gaba, L., and Angeles, M.A. (2022). Comparison of HE4, CA125, ROMA and CPH-I for preoperative assessment of adnexal tumors. Diagnostics, 12.","DOI":"10.3390\/diagnostics12010226"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cca.2021.11.018","article-title":"A combined strategy of TK1, HE4 and CA125 shows better diagnostic performance than risk of ovarian malignancy algorithm (ROMA) in ovarian carcinoma","volume":"524","author":"Zhu","year":"2022","journal-title":"Clin. Chim. Acta"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-08682-y","article-title":"Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient\u2019s plasma\u2014A prospective trial","volume":"21","author":"Hasenburg","year":"2021","journal-title":"BMC Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/diagnostics11010069","article-title":"Diagnostic value of plasma annexin a2 in early-stage high-grade serous ovarian cancer","volume":"11","author":"Lokman","year":"2021","journal-title":"Diagnostics"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/bjc.2017.199","article-title":"A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours","volume":"117","author":"Russell","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/s41416-019-0718-9","article-title":"Improved early detection of ovarian cancer using longitudinal multimarker models","volume":"122","author":"Whitwell","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ygyno.2017.04.005","article-title":"Autoantibody biomarkers for the detection of serous ovarian cancer","volume":"146","author":"Katchman","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/pr500908n","article-title":"Autoantibody signature for the serologic detection of ovarian cancer","volume":"14","author":"Anderson","year":"2015","journal-title":"J. Proteome Res."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Silwal-Pandit, L., Langer\u00f8d, A., and B\u00f8rresen-Dale, A.-L. (2017). Irminger-Finger BARD1 autoantibody blood test for early detection of ovarian cancer. Cold Spring Harb. Perspect. Med., 7.","DOI":"10.1101\/cshperspect.a026252"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1158\/1078-0432.CCR-17-0284","article-title":"Elevation of TP53 autoantibody before CA125 in preclinical invasive epithelial ovarian cancer","volume":"23","author":"Yang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/cas.14732","article-title":"Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer","volume":"112","author":"Ma","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1002\/jcb.27497","article-title":"Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer","volume":"120","author":"Wang","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s13277-014-2756-5","article-title":"Detection of autoantibodies to multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer","volume":"36","author":"Liu","year":"2015","journal-title":"Tumor Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"6657820","DOI":"10.1155\/2022\/6657820","article-title":"Serum Autoantibodies against LRDD, STC1, and FOXA1 as Biomarkers in the Detection of Ovarian Cancer","volume":"2022","author":"Duan","year":"2022","journal-title":"Dis. Markers"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Pilyugin, M., Ratajska, M., Stukan, M., Concin, N., Zeillinger, R., and Irminger-Finger, I. (2021). BARD1 autoantibody blood test for early detection of ovarian cancer. Genes, 12.","DOI":"10.3390\/genes12070969"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"698312","DOI":"10.3389\/fimmu.2021.698312","article-title":"Serum Anti-PDLIM1 autoantibody as diagnostic marker in ovarian cancer","volume":"12","author":"Qiu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Pessoa, L.S., Heringer, M., and Ferrer, V.P. (2020). ctDNA as a cancer biomarker: A broad overview. Crit. Rev. Oncol. Hematol., 155.","DOI":"10.1016\/j.critrevonc.2020.103109"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/15330338211043784","article-title":"The prognostic value of circulating tumor DNA in ovarian cancer: A meta-analysis","volume":"20","author":"Lu","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Li, B., Pu, K., Ge, L., and Wu, X. (2019). Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis. Gene, 714.","DOI":"10.1016\/j.gene.2019.143993"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.tibs.2010.05.003","article-title":"Glutamine addiction: A new therapeutic target in cancer","volume":"35","author":"Wise","year":"2010","journal-title":"Trends Biochem. Sci."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Morgan, S.R., Whiteley, J., Donald, E., Smith, J., Eisenberg, M.T., Kallam, E., and Kam-Morgan, L. (2012). Comparison of KRAS mutation assessment in tumor DNA and circulating free DNA in plasma and serum samples. Clin. Med. Insights Pathol., 15\u201322.","DOI":"10.4137\/CPath.S8798"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Gong, G., Lin, T., and Yuan, Y. (2020). Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer. J. Ovarian Res., 13.","DOI":"10.1186\/s13048-020-00632-9"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/ijc.32984","article-title":"Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer","volume":"147","author":"Singh","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2353\/jmoldx.2009.080072","article-title":"Differential methylation profile of ovarian cancer in tissues and plasma","volume":"11","author":"Melnikov","year":"2009","journal-title":"J. Mol. Diagn."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Singh, A., Gupta, S., and Sachan, M. (2021). Evaluation of the diagnostic potential of candidate hypermethylated genes in epithelial ovarian cancer in North Indian Population. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.719056"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3892\/ijo.2017.3948","article-title":"MicroRNAs driving invasion and metastasis in ovarian cancer: Opportunities for translational medicine (Review)","volume":"50","author":"Flores","year":"2017","journal-title":"Int. J. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13048-020-00648-1","article-title":"Serum exosomal microRNA-34a as a potential biomarker in epithelial ovarian cancer","volume":"13","author":"Maeda","year":"2020","journal-title":"J. Ovarian Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"81621","DOI":"10.18632\/oncotarget.13154","article-title":"miRNA-200a\/c as potential biomarker in epithelial ovarian cancer (EOC): Evidence based on miRNA meta-signature and clinical investigations","volume":"7","author":"Teng","year":"2016","journal-title":"Oncotarget"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13048-022-00961-x","article-title":"Detection of plasma exosomal miRNA-205 as a biomarker for early diagnosis and an adjuvant indicator of ovarian cancer staging","volume":"15","author":"Zhu","year":"2022","journal-title":"J. Ovarian Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/12041\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:49:13Z","timestamp":1760143753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/12041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":120,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ijms231912041"],"URL":"https:\/\/doi.org\/10.3390\/ijms231912041","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]}}}